LifeStance Health Group, Inc. (LFST)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Earnings Estimates Rising for LifeStance Health (LFST): Will It Gain?
LifeStance Health Group (LFST) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
LifeStance Health Group (LFST) is a Great Momentum Stock: Should You Buy?
Does LifeStance Health Group (LFST) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts See a 31.02% Upside in LifeStance Health (LFST): Can the Stock Really Move This High?
The consensus price target hints at a 31% upside potential for LifeStance Health (LFST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
LifeStance Health Group Q1 Earnings Call Highlights
LifeStance Health Group NASDAQ: LFST reported first-quarter 2026 results that management said exceeded expectations and prompted the company to raise full-year guidance across its key metrics. On the company's earnings call, CEO Dave Bourdon highlighted what he described as an “exceptional start to the year,” pointing to revenue growth of more than 21% and adjusted EBITDA topping $50 million.
LifeStance Health Group, Inc. (LFST) Q1 2026 Earnings Call Transcript
LifeStance Health Group, Inc. (LFST) Q1 2026 Earnings Call Transcript
LifeStance Health Group, Inc. (LFST) Q4 2025 Earnings Call Transcript
LifeStance Health Group, Inc. (LFST) Q4 2025 Earnings Call Transcript
LifeStance Health Group (LFST) Q4 Earnings and Revenues Top Estimates
LifeStance Health Group (LFST) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of breakeven. This compares to a loss of $0.02 per share a year ago.
Wall Street Analysts Think LifeStance Health (LFST) Could Surge 30.49%: Read This Before Placing a Bet
The mean of analysts' price targets for LifeStance Health (LFST) points to a 30.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts See a 33.38% Upside in LifeStance Health (LFST): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 33.4% in LifeStance Health (LFST). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
LifeStance Health Group, Inc. (LFST) Q3 2025 Earnings Call Transcript
LifeStance Health Group, Inc. ( LFST ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Monica Prokocki - Vice President of Investor Relations David Bourdon - CEO & Director Ryan McGroarty - CFO & Treasurer Conference Call Participants Craig Hettenbach - Morgan Stanley, Research Division Lisa Gill - JPMorgan Chase & Co, Research Division Matthew Mardula Brian Tanquilut - Jefferies LLC, Research Division Richard Close - Canaccord Genuity Corp., Research Division Kevin Caliendo - UBS Investment Bank, Research Division David Larsen - BTIG, LLC, Research Division Steven Dechert - KeyBanc Capital Markets Inc., Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. My name is Colby, and I'll be your conference operator today.
LifeStance Health Group (LFST) Reports Break-Even Earnings for Q3
LifeStance Health Group (LFST) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.02 per share a year ago.
All You Need to Know About LifeStance Health (LFST) Rating Upgrade to Strong Buy
LifeStance Health (LFST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
